Serological Immunoreactivity against Colon Cancer Proteome Varies upon Disease Progression

Sera from colon carcinoma patients were used to identify tumor-associated antigens (TAAs) by screening tumor proteome resolved by 2D electrophoresis. A panel of six TAAs eliciting a serological immune response in colorectal cancer was identified, showing a modification in antigen recognition by B ce...

Full description

Saved in:
Bibliographic Details
Published in:Journal of proteome research 2008-02, Vol.7 (2), p.504-514
Main Authors: De Monte, Lucia, Sanvito, Francesca, Olivieri, Stefano, Viganò, Fiammetta, Doglioni, Claudio, Frasson, Matteo, Braga, Marco, Bachi, Angela, Dellabona, Paolo, Protti, Maria Pia, Alessio, Massimo
Format: Article
Language:English
Subjects:
Adenocarcinoma - immunology
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Adult
Aged
Aged, 80 and over
Antibodies, Neoplasm - biosynthesis
Antibodies, Neoplasm - genetics
Antibodies, Neoplasm - metabolism
Antigens, Neoplasm - immunology
Antigens, Neoplasm - metabolism
Cell Line, Tumor
Colonic Neoplasms - immunology
Colonic Neoplasms - metabolism
Colonic Neoplasms - pathology
Disease Progression
Electrophoresis, Gel, Two-Dimensional
Female
HT29 Cells
Humans
Male
Middle Aged
Proteome - immunology
Proteome - metabolism
Proteomics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sera from colon carcinoma patients were used to identify tumor-associated antigens (TAAs) by screening tumor proteome resolved by 2D electrophoresis. A panel of six TAAs eliciting a serological immune response in colorectal cancer was identified, showing a modification in antigen recognition by B cells in patients as a function of colon cancer progression. The expression of these proteins was either confined or increased in tumor as compared to normal mucosa.
ISSN:1535-3893
1535-3907
DOI:10.1021/pr070360m